Alkermes’ Orexin-2 Receptor Agonist for Narcolepsy Enters Phase 2 Trials
The phase 2 trial will evaluate the safety and efficacy of ALKS 2680, a novel orexin-2 receptor agonist, in patients with narcolepsy type 1.
The phase 2 trial will evaluate the safety and efficacy of ALKS 2680, a novel orexin-2 receptor agonist, in patients with narcolepsy type 1.
The agreement grants NLS Pharmaceutics global rights to non-sulfonamide orexin-1/orexin-2 receptor agonists, with potential applications in narcolepsy and idiopathic hypersomnia.
Apnimed unveiled the full results of its MARIPOSA phase 2b trial of AD109, an investigational oral drug for obstructive sleep apnea.
Vanda Pharmaceuticals highlighted updates on regulatory efforts for Hetlioz, focusing on expanding its indications to include the treatment of insomnia and jet lag disorder.
Read MoreTakeda announced positive results from a phase 2b trial evaluating TAK-861, an oral orexin receptor 2 agonist, in patients with narcolepsy type 1.
Read MoreVanda received notification from the FDA regarding deficiencies in its supplemental new drug application for Hetlioz in treating insomnia.
Read MoreApnimed hired new leadership to build its capabilities in support of AD109, a potential nighttime oral treatment for OSA currently in phase 3 clinical trials.
Read MoreThe Institutional Review Board has approved the protocol for Incannex’s phase 2/3 clinical trial to be conducted in the United States to assess IHL-42X in patients with obstructive sleep apnea.
Read MoreBayer is starting a phase II study to evaluate elinzanetant in women with sleep disturbances associated with menopause.
Read MoreAxsome Therapeutics details anticipated milestones for investigational drugs for narcolepsy and excessive daytime sleepiness associated with shift work disorder.
Read MoreIn a letter to shareholders, the CEO of Swiss clinical-stage biopharmaceutical company NLS Pharmaceutics Ltd recapped the company’s progress and pitfalls for 2023.
Read MoreJazz Pharmaceuticals is pausing its phase 1 clinical trial investigating JZP441, an oral orexin-2 receptor agonist with potential application for the treatment of narcolepsy and other sleep disorders, after reports of adverse effects.
Read MoreThe investigational drug may be able to help patients with Alzheimer’s, Parkinson’s disease, and other central nervous system disorders who often concurrently experience insomnia and/or anxiety, according to the company.
Read MoreNLS Pharmaceutics is exploring strategic alternatives, including the out-licensing of its key asset Mazindol, to maximize shareholder value.
Read MoreCentessa Pharmaceuticals announced third-quarter updates for its narcolepsy drug candidate, ORX750, an orexin receptor 2 agonist.
Read MoreThe FDA has accepted a supplemental new drug application from Vanda Pharmaceuticals for Hetlioz (tasimelteon) in insomnia.
Read MoreThe investigational drug demonstrated a statistically significant and clinically meaningful reduction in excessive daytime sleepiness in adult narcolepsy patients.
Read MoreIn its third-quarter business update, Zevra Therapeutics Inc designated KP1077, its investigational drug in development for idiopathic hypersomnia and narcolepsy, as a pivotal focus area.
Read More